







: Non-motor symptoms (NMS) of
Parkinson's disease (PD) are a key determinant of health,
quality of life (QoL) and societal cost of PD. They are often
less appreciated than motor symptoms but are important
sources of disability for many PD patients.
: Literature search was performed using the
reference databases Medline, Science Citation Index and
EMBASE. The keywords used were 'non-motor
symptoms', Parkinson's disease, olfaction and
constipation. Papers discovered by this search were
reviewed, as were references cited therein.
: Contrary to common perception, many NMS of
PD occur early in PD and some may even predate the
diagnosis of PD that is based on motor signs. These
include olfactory deficit, sleep problems such as rapid eye
movement behaviour disorder, constipation and the more
recently described male erectile dysfunction.
: There is compelling evidence that non-
motor symptoms of PD play a dominant role in the QoL
and disability of PD patients and the QoL of their 'informal'
carers. Effective clinical management of PD therefore
demands that these symptoms be identified and to the
extent possible treated.
: Non motor symptoms, Parkinson's disease,
Non motor questionnaire, Constipation, Olfaction, male
erectile dysfunction
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Introduction
Parkinson's disease (PD) is the second most common
neurodegenerative disease. Characterized by the
cardinal signs of bradykinesia, rigidity, tremor at rest, and
abnormalities of balance, posture, and gait, the aetiology
of PD remains unknown in most patients. Sir James
Parkinson himself recognised Non-motor symptoms
(NMS) in PD. Thus, in his essay on the Shaking Palsy in
1817, he referred to sleep disturbance, constipation,
urinary incontinence and delirium. NMS in PD, a
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domains: autonomic, neuropsychaitric, and sensory,
including pain. However, despite their impact, the NMS
of PD are not well recognised in clinical practise and one
study in the United States of America reported that
existing depression, anxiety and fatigue are not
identified by neurologists in over 50% of consultations,
and sleep disturbance in over 40%. Another recent
study attempted to correlate NMS in PD at presentation
retrospectively after clinico-pathological confirmation of
diagnosis. Twenty-one percentage had NMS at
presentation and these included pain, anxiety, urinary
dysfunction and depression. It is commonly thought that
NMS occur only in late or advanced PD but NMS can
indeed present at any stage of the disease including
early and pre-motor phase of PD. Prospective data
based on the Honolulu Asia ageing and other studies
suggest that several NMS of PD such as olfactory
problems, constipation, depression and erectile
dysfunction may predate the motor signs, symptoms
and diagnosis of PD by a number of years. These data
indicate that NMS may appear early in the course of PD
and dominate the later stages of the disease. It has been
suggested that some NMS such as olfactory
dysfunction in combination with others such as rapid
eye behaviour disorder (RBD) or constipation may form
part of a battery of tests to identify a population “at risk of
PD”, which will be particularly important if and when
neuroprotective therapies become available (Table 1).
Stacy and co workers reported that NMS were present
even in patients within 5 years of motor disease onset,
and these were identified frequently with the use of a
patient-completed questionnaire. A comprehensive,
self-completed non-motor questionnaire for PD
(NMSQuest) was developed to help identify NMS. A
range of non-motor symptoms occurred in PD patients
from early to advanced disease. The NMSQuest
flagged up many NMS such as dribbling of saliva,
dysphagia and sexual problems that had not been
discussed with a doctor earlier. The study also
highlighted that, irrespective of country of study and
disease stage, most PD patients are likely to flag up 9 to
12 different NMS in the NMSQuest at clinic visit.
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NMS of PD, the PD non-motor scale (NMSS), have
indicated a strong relationship between the burden of
NMS in PD and health-related QoL. The exact
pathophysiology of NMS is still poorly understood.
Recent pathological evidence suggests that PD affects
the brain in six stages. The first two preclinical are
characterized by abnormalities in the olfactory bulb and
lower brain stem. Several NMS, including loss of smell,
sleep disturbances, and fatigue may occur during these
first stages and are preclinical markers of the disease.
Tremor, rigidity, and bradykinesia become evident in
stages 3 and 4 when the substantia nigra pars compacta
is affected. The neocortex and limbic system are affected
in stages 5 and 6, which may cause dementia and
hallucinations. Screening these early NMS might,
therefore, be one approach towards early 'preclinical'
diagnosis of PD. This review article provides an overview
of the clinical spectrum of NMS in PD together with a brief











Sleep disorders affect nearly all PD patients, appear early
in the clinical course of PD. They include insomnia,
parasomnias, RBD, restless legs syndrome, periodic limb
movements of sleep, vivid dreaming, and sleep apnea. In
addition, patients may experience disorders of
wakefulness, including excessive daytime sleepiness or
sudden-onset sleep (sleep attacks) with or without
concomitant sleep disorders.
(EDS) commonly occurs in
PD and frequently adversely affects QoL. EDS can be
caused by the disease itself, medications, or sleep
disorders. Predictors of EDS in PD include increasing
age, advanced disease and higher dosages of
doperminergic medications. Dopamine agonists (DAs) in
particular are a common cause of EDS in patients with




Table I A list of non-motor symptoms suggested as pre-clinical
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warranted for patients with EDS. Assessments that can
be useful include Parkinson's Disease Sleep Scale ,
SCOPA sleep , and Epworth Sleepiness Scale (not
specific for PD). If no treatable sleep disorder is
identified, treatment with modafinil or other wake-
promoting agents can be considered. Several
trials have evaluated the use of modafinil, a wake-
promoting agent that is approved for use in narcolepsy,
for treating EDS in PD. Results of these trials are
conflicting and range from modest improvement to lack
of efficacy. The dose range of modafinil in these studies
was 200 mg/day to 400 mg/day.
is very common in PD and causes patients to
be unable to fall asleep or maintain sleep. It can be
treated by having the patient adhere to a consistent
sleep schedule, attempt to avoid daytime napping, and
abstain from alcohol, caffeine, tobacco and other
stimulants in the evening hours. A review of all current
medications is warranted to identify those that might be
causing insomnia. Depression and anxiety should be
treated. Some patients may require the use of hypnotics
such as zalepion or trazadone to treat insomnia.
(RBD)
RBD is a parasomnia characterized by loss of normal
skeletal muscle atonia during REM sleep when
dreaming occurs, leading to “acting out of dreams,”
including sleep talking, shouting, and intense,
sometimes violent movements. Patients may
inadvertently injure their bed partners by punching or
choking them. RBD has been reported in 25% to 50%
of patients with PD and can precede the onset of PD by
several years. Clonazepam can be used in dosages
of 0.5 mg to 2 mg at bedtime to treat RBD.
The syndrome of restless legs occur in approximately
20% of patients with PD. It causes patients to
experience an urge to move their legs, usually
accompanied by uncomfortable leg sensations. It is
common in the elderly in Western populations, in which
restless legs syndrome affects 8 to 10% of subjects over
65 years of age. DAs, including ropinirole and
pramipexole may be used to treat restless legs
syndrome in PD. Opiods can also be used but may
cause dependency.
Fatigue has been reported in 75% PD patients and is
more prevalent in patients with PD than in age-matched
controls. It is characterized by a feeling of lack of energy












REM sleep behaviour disorder
Restless legs syndrome
Fatigue
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QoL. The cause of fatigue in PD is unclear, and it does not
clearly correlate with the severity of motor symptoms,
depression, or dosage or duration of PD medications.
Assessment that can be useful include Fatigue Severity
Scale and Parkinson Fatigue Scale (PFS-16)-self report
Treatment for fatigue in PD have not been well
evaluated, although modafinil and other stimulants have
been used anecdotally.
Obstructive sleep apnoea occurs in about 20% of patients
with PD and is defined by intermittently absent or
reduced airflow during sleep despite respiratory effort.
However, patients may not give a history of snoring, and
there is a suggestion that PD patients with sleep apnoea
need not be obese. Treatment usually consists of wearing
an airflow mask, although many patients find it
uncomfortable.
The prevalence of orthostatic dizziness, constipation,
bladder dysfunction, erectile dysfunction, and
hyperhidrosis is significantly higher among PD patients
than matched controls. Orthostatic hypotension is
defined as a drop of 30 mmHg in systolic blood pressure
or a drop of 20 mmHg in mean blood pressure when rises
to standing from supine position. Orthostatic hypotension
and dizziness are associated with an increased risk of
falls and resulting fractures. Treatment consists of
adequate hydration with eight or more glasses of fluid
each day, and the use of mineralocorticoids, such as
fludrocortisone, to increase intravascular volume. Other
frequently experienced autonomic symptoms in a
prospective clinic-based survey of patients with six years
of disease duration and more advanced disease were
hypersalivation (14%), sexual dysfunction (18%), urinary
problems (22%), sweating disorder (24%) and
constipation (59%). Potentially useful assessment of
autonomic dysfunction include: SCOPA-AUT- a
questionnaire to evaluate autonomic dysfunction in Pd  ,
QSART- quantitative sudomotor axon reflex for
sudomotor function and urodynamic studies for
uroflowmetry and cystometry.
Cognitive impairment may be present even in the early
stages of PD. Estimates of the prevalence of cognitive
impairment in PD range from 20% to 93% depending
probably on how cognitive impairment is defined and
assessed. In a community-based survey in early PD, 36%
of the patients had evidence of cognitive impairment at












Cognitive impairment and dementia
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disease varies somewhat, but executive impairment,
including working memory and attention shift, and visuo-
spatial dysfunction characterize early cognitive
impairment in PD. Dementia in PD is associated with
longer disease duration and older age at onset and is a
risk factor for nursing home placement and is associated
with shorter life expectancy. Assessments that can be
useful include SCOPA-Cog- a short, reliable instrument
sensitive to the specific cognitive deficits in PD and Mini-
Mental State Examination (MMSE). Although
commonly used to screen for cognitive decline, the
MMSE has not been specifically validated in PD and
parts requiring a degree of motor skill should probably
be discounted. Rivastigmine, a cholinesterase inhibitor,
is now approved for use in treating dementia in PD. In a
placebo-controlled study, PD patients with mild to
moderate dementia were randomly assigned to receive
placebo or 3 mg to 12 mg of rivastigmine per day for 24
weeks. Moderate improvements in dementia were
noted with rivastigmine use, but there were also higher
rates of nausea, vomiting and tremor. Despite the
growing literature suggesting benefits of cholinesterase
inhibitors therapy, more studies are needed to clarify
whether differences exist among the various
cholinesterase inhibitors.
Neuropsychiatric disorders are important determinants
of QoL and caregiver burden in PD. In a population-
based study of 139 patients with PD, 61% suffered from
at least one neuropsychiatric symptom after 12 years of
disease duration. The most common behaviours found
were depression (38%) and hallucinations (27%).
Psychotic symptoms in PD (PDPsy) include illusions,
the sense of presence, simple and complex
hallucinations with and without insight, and delusions.
Visual hallucinations are found to be the most common
form, while auditory, olfactory and tactile hallucination
are less frequent and usually present together with
visual hallucination. PDPsy in patients with PD
rarely occurred before the introduction of dopaminergic
treatment. Dopaminergic agents are therefore
understood as an important cause of psychotic
symptoms and abnormal behaviour in PD. Reported
prevalence rates of hallucination vary, most likely due to
differences in patient selection and study design, and
range from 16% to 75% in prospective cross-sectional
studies. Hallucinations are one of the main features
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Depressive symptoms are significantly more common in
PD than in age-matched controls and patients with other
chronic diseases. They may occur many years before
the motor onset of PD. About 20% of patients report
depressive symptoms before diagnosis, and the risk for
developing PD is 2-3 fold increased in depressed patients
compared to non-depressed control subjects. In a
recent systematic review of prevalence studies of
depression in PD, frequency rates ranged from 12.7% to
about 90% in clinical-based studies fulfilling quality
criteria for inclusion. This variation is likely to be the
result of methodological differences between studies in
the studies included. Antidepressants, including tricyclics
and selective serotonin reuptake inhibitors (SSRIs) have
been found to improve depression in patients with PD,
and the DA pramipexole may have antidepressant
efficacy.
Olfactory dysfunction in PD includes impairment of odour
detection, differentiation, and identification, and is
persistent and not influenced by drug treatment. In the
light of Braak's hypothesis of a stagewise progression of
pathological changes in PD, indicating presymptomatic
lesions in the olfactoric tract, attention has been drawn to
patients primarily diagnosed with idiopathic hyposmia.
Recent evidence suggests that these persons are at
increased risk of developing PD later during life.
Olfactory dysfunction is increasingly recognised as a
frequent feature in overt PD , but its prevalence in the
general PD population is unknown. Most patients showing
deficits in olfactory tests are unaware of a smell disorder.
Several complications apparently related to high-dose
dopaminergic treatments for PD are comparatively
infrequent, but deserve attention because they are
socially disabling when they occur.
Punding involves compulsive, stereotypical, repetitive
and purposeless behaviours that are similar, but distinct
from obsessive-compulsive disorder. In a series of 50
patients with higher dopamine replacement therapy
(>800 levodopa [L-dopa] equivalent units/day), from 123
unselected PD patients Evans et al identified 17(14%)
patients with punding. Management of punding involves
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cases, Meseguer reported improvement in all with
reduction of dopaminergic doses. There is neither any
specific scale nor screening instrument to assess
punding nor common diagnostic criteria. Clinicians will
need to rely upon interviews as patients with punding
appear to be aware of their behaviour but information
from caregivers may be most helpful.
Pathological gambling is one of the impulse control
disorders that can have disastrous consequences and
is related to dopaminergic agonists. In a series of 297
PD patients and using rigorous criteria for impulse
control disorders (ICDs), Voon et al found lifetime
prevalence of 3% for pathological gambling, 2.4% for
pathological hypersexuality and 0.7% for compulsive
shopping, giving lifetime prevalence of these ICDs of
6.1%, which increased to 13.7% in patients on
dopamine agonists.
There is an association between the severity of motor
symptoms and the incidence of non-motor symptoms,
but the relationship is weak and non-motor symptoms
are characteristically unresponsive to L-dopa. 61
Because NMS are generally unresponsive to
dopaminergic drugs, clinical management will require
interventions commonly used to treat the emergent
symptom, but keeping in mind that PD patients are often
elderly, at risk for drug-drug interactions and often
require doses differing from those for healthy adults.
PD is the second most common neurodegenerative
disorder. Non-motor features such as constipation,
olfactory dysfunction, depression, anxiety, and sleep
disorders may precede the motor onset of the disease.
There is compelling evidence the NMS of PD play a
dominant role in the QoL and disability of PD patients
and the QoL of their 'informal' carers. Effective clinical
management of PD therefore demands that these
symptoms be identified and to the extent possible,
treated. Treatment can be challenging, as these
symptoms are often unresponsive to conventional
dopaminergic therapy. However, the importance of a
multi-professional team-neurologist, specialist nurse,





Treatment of non-motor symptoms
Summary and conclusions
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